Repare Therapeutics Inc. announced the appointment of Philip Herman as its EVP Commercial & New Product Development. Mr. Herman joins Repare from Y-mAbs Therapeutics, where he served as Chief Commercial Officer and led the successful launch of DANYELZA® (naxitamab).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.99 USD | +5.00% | -0.75% | -45.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.34% | 161M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- RPTX Stock
- News Repare Therapeutics Inc.
- Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development